Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease | Zendy

Robert Zeiser | Zendy; Nicola Polverelli | Zendy; Ron Ram | Zendy; Shahrukh K. Hashmi | Zendy; Ronjon Chakraverty | Zendy; Jan Moritz Middeke | Zendy; Maurizio Musso | Zendy; Sebastian Giebel | Zendy; Ant Uzay | Zendy; Peter Langmuir | Zendy; Norbert Hollaender | Zendy; Maanasa Gowda | Zendy; Tommaso Stefanelli | Zendy; Stephanie J. Lee | Zendy; Takanori Teshima | Zendy; Franco Locatelli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

Author(s) -

Robert Zeiser,

Nicola Polverelli,

Ron Ram,

Shahrukh K. Hashmi,

Ronjon Chakraverty,

Jan Moritz Middeke,

Maurizio Musso,

Sebastian Giebel,

Ant Uzay,

Peter Langmuir,

Norbert Hollaender,

Maanasa Gowda,

Tommaso Stefanelli,

Stephanie J. Lee,

Takanori Teshima,

Franco Locatelli

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2033122

Subject(s) - ruxolitinib , glucocorticoid , refractory (planetary science) , graft versus host disease , host (biology) , medicine , disease , immunology , biology , genetics , bone marrow , astrobiology , myelofibrosis

Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients. Robust data from phase 3 randomized studies evaluating second-line therapy for chronic GVHD are lacking. In retrospective surveys, ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory or -dependent chronic GVHD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research